0001193125-23-118572.txt : 20230426 0001193125-23-118572.hdr.sgml : 20230426 20230426162600 ACCESSION NUMBER: 0001193125-23-118572 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230420 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20230426 DATE AS OF CHANGE: 20230426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDICINOVA INC CENTRAL INDEX KEY: 0001226616 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330927979 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33185 FILM NUMBER: 23850127 BUSINESS ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE STREET 2: SUITE 300 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-373-1500 MAIL ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE STREET 2: SUITE 300 CITY: LA JOLLA STATE: CA ZIP: 92037 8-K 1 d467282d8k.htm 8-K 8-K
MEDICINOVA INC DE false 0001226616 0001226616 2023-04-20 2023-04-20

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 20, 2023

 

 

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   001-33185   33-0927979

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

4275 EXECUTIVE SQUARE,

SUITE 300, LA JOLLA, CA

  92037
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 373-1500

Not applicable.

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Common Stock, $0.001 par value

 

MNOV

 

The Nasdaq Stock Market LLC

(Title of each class)   (Trading symbol(s))   (Name of each exchange
on which registered)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.02

Departure of Directors or Certain Officers; Election; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 20, 2023, Jeff Himawan, Ph.D., a member of the Board of Directors (the “Board”) of MediciNova, Inc. (the “Company”) notified the Board that he will not stand for re-election as a Class I director of the Company at the Company’s 2023 annual meeting of stockholders (the “Annual Meeting”) due solely to a personal decision related to health reasons. Dr. Himawan’s decision to not stand for re-election was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Dr. Himawan’s term will end at the Annual Meeting and his seat will remain vacant until filled in accordance with the Company’s Amended and Restated Bylaws. The Company thanks Dr. Himawan for his leadership and service.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MEDICINOVA, INC.
    By:  

/s/ Yuichi Iwaki

     

Yuichi Iwaki

President and Chief Executive Officer

Date: April 26, 2023      
EX-101.SCH 2 mnov-20230420.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 mnov-20230420_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 mnov-20230420_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Apr. 20, 2023
Cover [Abstract]  
Entity Registrant Name MEDICINOVA INC
Entity Incorporation State Country Code DE
Amendment Flag false
Entity Central Index Key 0001226616
Document Type 8-K
Document Period End Date Apr. 20, 2023
Entity File Number 001-33185
Entity Tax Identification Number 33-0927979
Entity Address, Address Line One 4275 EXECUTIVE
Entity Address, Address Line Two SQUARE
Entity Address, Address Line Three SUITE 300
Entity Address, City or Town LA JOLLA
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code (858)
Local Phone Number 373-1500
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol MNOV
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d467282d8k_htm.xml IDEA: XBRL DOCUMENT 0001226616 2023-04-20 2023-04-20 MEDICINOVA INC DE false 0001226616 8-K 2023-04-20 001-33185 33-0927979 4275 EXECUTIVE SQUARE SUITE 300 LA JOLLA CA 92037 (858) 373-1500 false false false false Common Stock, $0.001 par value MNOV NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode, dei:EntityRegistrantName - d467282d8k.htm 7 d467282d8k.htm mnov-20230420.xsd mnov-20230420_lab.xml mnov-20230420_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d467282d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d467282d8k.htm" ] }, "labelLink": { "local": [ "mnov-20230420_lab.xml" ] }, "presentationLink": { "local": [ "mnov-20230420_pre.xml" ] }, "schema": { "local": [ "mnov-20230420.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mnov", "nsuri": "http://www.medicinova.com/20230420", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d467282d8k.htm", "contextRef": "duration_2023-04-20_to_2023-04-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d467282d8k.htm", "contextRef": "duration_2023-04-20_to_2023-04-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com//20230420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001193125-23-118572-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-118572-xbrl.zip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end